A Phase 2 interventional study of Cilofexor and Placebo to match cilofexor in Primary Biliary Cholangitis, sponsored by Gilead Sciences. Terminated at 25 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-09-22.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 8th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 2nd registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Gilead Sciences · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 126 across the 10 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of cilofexor in adults with primary biliary cholangitis (PBC).
Key Inclusion Criteria:
Meets all of the following conditions
Definite or probable PBC as defined by at least 2 of the 3 following criteria:
Key Exclusion Criteria:
Cirrhosis of the liver as defined by any of the following:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
Drug: Cilofexor · Drug: Placebo to match cilofexor
Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.
Drug: Cilofexor · Drug: Placebo to match cilofexor
Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
Drug: Placebo to match cilofexor
Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.
Drug: Cilofexor
Tablet(s) administered orally once daily, with food
Also known as: GS-9674
Tablet(s) administered orally once daily, with food
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) in the Blinded Study Phase
Time frame: First dose date up to Week 12 + 30 days
Percentage of Participants Experiencing TEAEs and TESAEs in the Open-Label Extension (OLE) Phase
Time frame: First dose date in the OLE phase up to last dose date (Maximum: 97.4 weeks) + 30 days
Percentage of Participants Who Experienced Graded Laboratory Abnormalities in the Blinded Study Phase
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
Time frame: First dose date up to Week 12 + 30 days
Percentage of Participants Who Experienced Graded Laboratory Abnormalities in the OLE Phase
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
Time frame: First dose date in the OLE phase up to last dose date (Maximum: 97.4 weeks) + 30 days
Participants were enrolled at study sites in United States, Canada, United Kingdom, and Austria. The first participant was screened on 01 December 2016. The last study visit occurred on 4 September 2019.
| Milestone | Cilofexor 100 mg | Cilofexor 30 mg | Placebo |
|---|---|---|---|
| Started | 28 | 30 | 13 |
| Completed | 23 | 28 | 12 |
| Not completed | 5 | 2 | 1 |
| Withdrew: Withdrew consent | 1 | 2 | 1 |
| Withdrew: Adverse event | 3 | 0 | 0 |
| Withdrew: Investigator's discretion | 1 | 0 | 0 |
| Milestone | Cilofexor 100 mg | Cilofexor 30 mg | Placebo |
|---|---|---|---|
| Started | 23 | 28 | 12 |
| Completed | 5 | 3 | 2 |
| Not completed | 18 | 25 | 10 |
| Withdrew: Study terminated by sponsor | 10 | 12 | 6 |
| Withdrew: Adverse event | 4 | 7 | 3 |
| Withdrew: Lack of efficacy | 3 | 4 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| percentage of participants | Blinded Study Phase: Cilofexor 100 mg | Blinded Study Phase: Cilofexor 30 mg | Blinded Study Phase: Placebo |
|---|---|---|---|
| TEAEs | 89.3 | 76.7 | 84.6 |
| TESAEs | 0 | 3.3 | 0 |
| percentage of participants | OLE Phase: From Cilofexor 100 mg | OLE Phase: From Cilofexor 30 mg | OLE Phase: From Placebo |
|---|---|---|---|
| TEAEs | 95.7 | 89.3 | 100.0 |
| TESAEs | 4.3 | 0 | 0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Blinded Study Phase: Cilofexor 100 mg | Blinded Study Phase: Cilofexor 30 mg | Blinded Study Phase: Placebo |
|---|---|---|---|
| Any Graded Laboratory Abnormality | 85.7 | 86.7 | 92.3 |
| Grade 4 or above Laboratory Abnormalities | 0 | 3.3 | 0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | OLE Phase: From Cilofexor 100 mg | OLE Phase: From Cilofexor 30 mg | OLE Phase: From Placebo |
|---|---|---|---|
| Any Graded Laboratory Abnormality | 91.3 | 96.4 | 100.0 |
| Grade 4 or above Laboratory Abnormalities | 0 | 0 | 0 |
Collected over Blinded Study Phase: First dose date up to Week 12 + 30 days; Open-label Extension (OLE) Phase: First dose date in the OLE Phase up to last dose date (Maximum: 97.4 weeks) + 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinded Study Phase: Cilofexor 100 mg | 0/28 (0%) | 0/28 (0%) | 21/28 (75%) |
| Blinded Study Phase: Cilofexor 30 mg | 0/30 (0%) | 1/30 (3.3%) | 18/30 (60%) |
| Blinded Study Phase: Placebo | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| OLE Phase: From Cilofexor 100 mg | 0/23 (0%) | 1/23 (4.3%) | 20/23 (87%) |
| OLE Phase: From Cilofexor 30 mg | 0/28 (0%) | 0/28 (0%) | 25/28 (89.3%) |
| OLE Phase: From Placebo | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | Blinded Study Phase: Cilofexor 100 mg | Blinded Study Phase: Cilofexor 30 mg | Blinded Study Phase: Placebo | OLE Phase: From Cilofexor 100 mg | OLE Phase: From Cilofexor 30 mg | OLE Phase: From Placebo |
|---|---|---|---|---|---|---|
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/28 | 0/30 | 0/13 | 1/23 | 0/28 | 0/12 |
| AppendicitisInfections and infestations | 0/28 | 1/30 | 0/13 | 0/23 | 0/28 | 0/12 |
| Event | Blinded Study Phase: Cilofexor 100 mg | Blinded Study Phase: Cilofexor 30 mg | Blinded Study Phase: Placebo | OLE Phase: From Cilofexor 100 mg | OLE Phase: From Cilofexor 30 mg | OLE Phase: From Placebo |
|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 13/28 | 6/30 | 3/13 | 4/23 | 11/28 | 6/12 |
| DiarrhoeaGastrointestinal disorders | 4/28 | 4/30 | 1/13 | 1/23 | 6/28 | 4/12 |
| HeadacheNervous system disorders | 4/28 | 4/30 | 4/13 | 2/23 | 1/28 | 0/12 |
| NauseaGastrointestinal disorders | 3/28 | 2/30 | 3/13 | 3/23 | 2/28 | 2/12 |
| FatigueGeneral disorders | 5/28 | 2/30 | 3/13 | 3/23 | 4/28 | 2/12 |
| ConstipationGastrointestinal disorders | 2/28 | 1/30 | 2/13 | 2/23 | 0/28 | 2/12 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/28 | 0/30 | 0/13 | 1/23 | 0/28 | 2/12 |
| InfluenzaInfections and infestations | 2/28 | 0/30 | 0/13 | 1/23 | 0/28 | 2/12 |
| NasopharyngitisInfections and infestations | 4/28 | 5/30 | 1/13 | 3/23 | 4/28 | 1/12 |
| Urinary tract infectionInfections and infestations | 2/28 | 2/30 | 0/13 | 2/23 | 2/28 | 2/12 |
The Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 54 ± 9.8 | 57 ± 6.3 | 58 ± 5.9 | 56 ± 7.9 |
| Sex: Female, Male(Participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 28 | 26 | 12 | 66 |
| Male | 0 | 4 | 1 | 5 |
| Race/Ethnicity, Customized(Participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Race — Asian | 2 | 0 | 0 | 2 |
| Race — Black or African American | 0 | 1 | 0 | 1 |
| Race — White | 26 | 27 | 13 | 66 |
| Race — Not Permitted | 0 | 1 | 0 | 1 |
| Race — Other | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 1 | 1 | 2 | 4 |
| Ethnicity — Not Hispanic or Latino | 26 | 28 | 11 | 65 |
| Ethnicity — Not Permitted | 1 | 1 | 0 | 2 |
| Region of Enrollment(participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Canada | 9 | 9 | 3 | 21 |
| Austria | 4 | 2 | 1 | 7 |
| United States | 12 | 16 | 7 | 35 |
| United Kingdom | 3 | 3 | 2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Sep 2019, 33 months.
Results were first posted in Jan 2020, 4 months after primary completion. A results delay was requested in Jun 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilofexor